WntResearch announced that the company, after a very fast patient recruitment, has been able to determine that the highest evaluated dose (8 mg/kg) of the drug candidate Foxy-5 will be used in the next step of the proof of concept study NeoFox. Approximately 80 patients with colon cancer will be treated in the second part of the study and an initial efficacy analysis is planned as early as the end of 2024. Previously reported ad hoc observations in patients with colon cancer indicate that the company's drug candidate Foxy-5 has a tumor-inhibiting effect already after three weeks of treatment.

Based on the positive observations with Foxy-5, as well as the drug candidate's very favorable safety profile, the study plan for the clinical phase 2 study NeoFox has been optimized with the goal of being able to show early effects of Foxy-5. An important part of this work has been the dose-finding stage of the study, which has now been completed after very rapid patient recruitment. The results show that it is safe to proceed with the highest evaluated dose, 8 mg/kg, in the next part of the study. The dose selection has been approved by the study's Safety Committee.

The Phase 2 clinical trial NeoFox aims to establish proof of concept for the drug candidate Foxy-5 in the treatment of colon cancer. Patients in the study receive the first dose of Foxy-5 after diagnosis and are then treated for three weeks until the primary tumor is surgically removed. WntResearch is planning an initial efficacy analysis of the data towards the end of 2024.

The purpose of this initial analysis is to evaluate the efficacy of Foxy-5 and at the same time assess whether the planned number of 80 patients is optimal for the study as a whole to demonstrate the desired effect. Final study results are expected in 2025.